Despite promising clinical evidence, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is facing considerable resistance from pharmacy benefit managers. The companies are https://vinnycgyy837595.blogdun.com/42742301/company-s-drug-faces-is-meeting-managed-care-organization-obstacles-a-review-of-coverage-fights